Nature News
September 3, 2009
India has rejected applications for patents from two US drug pharmaceutical companies for two AIDS drugs which could mean that more poor people in poor countries will have access to life saving medicines. The decisions are the latest in a string of legal victories for Cipla, India's largest generic drug maker. The move could also signal that patent offices in emerging economies are set to take a tougher line than industrialized countries on which drugs deserve patents. The drugs rejected are Gilead's drug Tenofovir and Tibotec's drug Darunavir.
Posts
No comments:
Post a Comment